Brief: Ekso Bionics Receives FDA Clearance To Market Its Eksonr Robotic Exoskeleton For Use With Multiple Sclerosis Patients
13/06/2022 13:25
June 13 (Reuters) - Ekso Bionics Holdings Inc EKSO.O :
* EKSO BIONICS RECEIVES FDA CLEARANCE TO MARKET ITS EKSONR™
ROBOTIC EXOSKELETON FOR USE WITH MULTIPLE SCLEROSIS PATIENTS
Source text for Eikon: ID:nGNX62Rp7z
Further company coverage: EKSO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Chronoscale
See all newsBrief: Soluna To Form Strategic Partnership With Applied Digital For Wind-Powered AI Data Center In Texas
Brief: Chronoscale Announces Agreements Bringing Total Company Contracted Run-Rate Revenue To $1 Billion And Sale Of Ekso Bionics Business Unit
U.S. STOCKS ON THE MOVE-BWX Technologies, Synopsys,Burlington Stores
U.S. STOCKS ON THE MOVE-Jazz Pharmaceuticals, Celularity, Infleqtion
U.S. STOCKS ON THE MOVE-Veeva Systems, Dollar General, ChronoScale